Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P240012/S007

AeroPace System

Lungpacer Medical USA, Inc. · Decision date Jun 22, 2026

FDA DECISIONP240012/S007

What did the FDA approve?

FDA records P240012/S007 as a supplement to PMA P240012, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Jun 22, 2026.

FDA approval order statement

Approval of the revised protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P240012
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Anesthesiology
Decision date
Jun 22, 2026
FDA change category
Postapproval Study Protocol

FDA source record

Regulatory record facts

Identifier
P240012/S007
Regulatory pathway
PMA supplement
Product code
SDL
Decision code
APPR
Decision date
Jun 22, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Transvenous temporary phrenic nerve stimulator.

Product code
SDL
FDA device class
3

For the original device and its historical approval scope, see PMA P240012. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P240012/S007 received

    Application receipt date recorded by FDA.

  2. P240012/S007 · FDA decision

    Normal 180 Day Track No User Fee

Timeline entries are records held by MedtechLedger for P240012. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240012

Product / regulatory recordCompanyPathwayDecision dateSource
Lungpacer Medical USA, Inc.PMA approvalDec 4, 2024FDA
AeroPace SystemP240012/S002
Lungpacer Medical USA, Inc.PMA supplementSep 23, 2025FDA
AeroPace SystemP240012/S003
Lungpacer Medical USA, Inc.PMA supplementSep 29, 2025FDA
AeroPace SystemP240012/S004
Lungpacer Medical USA, Inc.PMA supplementJan 14, 2026FDA
AeroPace SystemP240012/S005
Lungpacer Medical USA, Inc.PMA supplementFeb 20, 2026FDA
AeroPace SystemP240012/S006
Lungpacer Medical USA, Inc.PMA supplementJun 22, 2026FDA
AeroPace SystemP240012/S008
Lungpacer Medical USA, Inc.PMA supplementSep 25, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Lungpacer Medical USA, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
260 Sierra Dr., Suite 116, Exton, PA, 19341

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records